Orexo AB (publ) (STO:ORX)
Sweden flag Sweden · Delayed Price · Currency is SEK
19.00
0.00 (0.00%)
Jul 17, 2025, 5:29 PM CET

Orexo AB Company Description

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally.

Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia.

The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis.

In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder.

The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology.

Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.

Orexo AB (publ)
Orexo AB logo
CountrySweden
Founded1994
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees110
CEONikolaj Sorensen

Contact Details

Address:
Rapsgatan 7E
Uppsala, Uppsala County Uppsala County
Sweden
Phone46 1 87 80 88 00
Websiteorexo.com

Stock Details

Ticker SymbolORX
ExchangeNasdaq Stockholm
Fiscal YearJanuary - December
Reporting CurrencySEK
ISIN NumberSE0000736415
SIC Code2834

Key Executives

NamePosition
Nikolaj SorensenPresident and Chief Executive Officer
Fredrik JarrstenExecutive Vice President and Chief Financial Officer
Cecilia CouplandSenior Vice President and Head of Operations
Lena WangeInvestor Relations and Communications Director
Robert RonnSenior Vice President and Head of Research & Development
Dr. Edward Kim M.B.A., M.D.Chief Medical Officer
Robert A. Deluca BS PharmPresident of Orexo US Inc
Jesper LindAdvisor